A Large Retrospective Cohort Study on the Risk of Alzheimer’s Disease and Related Dementias in Association with Vascular Diseases and Cancer Therapy in Men with Prostate Cancer - 21/11/24
, L. Song 1, 2
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
No study was conducted on the long-term risk of Alzheimer’s disease (AD) and related dementias (ADRD) in association with vascular diseases in men with prostate cancer.
Objectives |
To determine the 26-year risk of ADRD in association with cardiovascular disease (CVD), stroke, hypertension, and diabetes in a nationwide cohort of men with prostate cancer.
Design |
Retrospective cohort study.
Setting |
Surveillance, Epidemiology, and End Results (SEER) areas of the United States.
Participants |
351,571 men diagnosed with prostate cancer at age ≥65 years.
Measurements |
Main exposures were CVD, stroke, hypertension, and diabetes. Main outcome was the incidence of ADRD.
Results |
The crude 26-year cumulative incidence of any ADRD was higher in those with versus without CVD (33.80% vs 29.11%), stroke (40.70% vs 28.03%), hypertension (30.88% vs 27.31%), and diabetes (32.23% vs 28.68%). Men with CVD (adjusted hazard ratio: 1.17, 95% CI: 1.15–1.20), stroke (1.59, 1.56–1.61), hypertension (1.13, 1.11–1.14), and diabetes (1.25, 1.23–1.27) were significantly more likely to develop ADRD than those without. Patients with 4 of these vascular diseases were 161% more likely to develop ADRD (2.61, 2.47–2.76) than those without. The risk of AD (0.89, 0.87–0.91) and ADRD (0.91, 0.90–0.93) became significantly lower in men with prostate cancer who received androgen deprivation therapy as compared to those who did not after considering death as a competing risk.
Conclusions |
In men with prostate cancer, vascular diseases were associated with significantly higher risks of developing ADRD. Androgen deprivation therapy was associated with a significantly decreased risk of AD in men with prostate cancer.
Le texte complet de cet article est disponible en PDF.Key words : Alzheimer’s disease, dementias, vascular diseases, prostate cancer, Medicare
Plan
| Declaration of interests: All other authors declare that there are no competing interests. |
|
| Data sharing: The National Cancer Institute’s SEER (Surveillance, Epidemiology, and End Results)-Medicare Data User Agreement (DUA) specifically requests that “You (the Investigators) will not permit others to use the data except for collaborators within your institution involved with the research as described in your proposal”. However, the SEER-Medicare linked data are available to researchers from the National Cancer Institute upon signing the DUA, having the study proposal approved, and paying the related costs, which is available in their website: seermedicare/. We plan to share the statistical models and statistical programs that we used to analyze these data upon request and to share study findings and related study resources. We also plan to make results and algorithms available for verification or replication by other researchers. |
Vol 10 - N° 2
P. 193-206 - avril 2023 Retour au numéro
Article précédent
- Fructose Consumption is Associated with a Higher Risk of Dementia and Alzheimer’s Disease: A Prospective Cohort Study
- J. Yan, K. Zheng, X. Zhang, Yingsong Jiang
- The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort
- Victor Bloniecki, J. Ulfvarson, K. Javanshiri, G. Hagman, Y. Freund-Levi, A. Nordströmg
Bienvenue sur EM-consulte, la référence des professionnels de santé.